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Background on Lung Caner and the EML4-ALK Oncogene
Lung cancer is the most prevalent of cancers and non-small cell lung cancer
(NSCLC) is the most fatal. Lung cancer accounts for about 32% of cancers in men and
25% in women. Of those cases of lung cancer, about 85% are NSCLC and it is usually
detected at an advanced stage (9, 11). Of all the NSCLC, 2-7% are ALK-positive,
meaning they have a genetic mutation that causes the overproduction of an unregulated,
activated oncoprotein responsible for intracellular communication. The constitutively
active signaling that is unchecked leads to ‘oncogene addiction.’ ‘Oncogene addiction’
means that the cancer’s sole driving force is this specific mutated gene and its products
(4,1). The ALK-positive mutation is most commonly found in younger, never (or former,
light) smokers that have an adenocarcinoma subtype (1). While the stated percentage of
possible patients is relatively low, the 2-7% of NSCLC that is ALK-positive translates
into more than 10,000 new cases annually in the United States alone (7).
The specific cancerous target of crizotinib that will be focused on is the EML4ALK protein. This protein appears in cancers with a genetic rearrangement that occurs in
the short arm of chromosome 2 (1). This genetic mutation involves the fusion of the Nterminal end of the echinoderm microtubule-associated protein-like 4 (EML4) gene and
the portion of the anaplastic lymphoma kinase (ALK) gene that encodes the entire
intracellular tyrosine kinase domain. There have been many different truncations of the
EML4 gene observed in these mutations but they always contain the coiled-coil domain
and the ALK gene has always been observed to break at intron 20 (8). The result of the
mutation is the EML4-ALK oncogene that encodes an enzyme that is capable of
activating pro-survival signaling pathways that prevent cell apoptosis, increase cell

growth and proliferation and aid in cell survival (1,6). The lack of death in these cells,
and their ability to live and thrive for longer periods of time then their un-mutated
counterparts, allows them to multiply and spread rapidly, making the EML4-ALK fusion
protein the prominent driver of tumor growth. Cancers expressing the EML4-ALK
oncoprotein are termed ALK-positive.
The un-mutated ALK enzyme is believed to play an important role in embryonic
neurogenesis but its expression decreases significantly shortly after birth and the low
levels are maintained throughout adulthood (8). In adults, it is believed that ALK may be
partially responsible for the regeneration of axons in damaged motor neurons but mice
with ALK knocked out are viable and fertile (1). In fact, they tended to perform better
than their wild type counterparts in experimental models of clinical depression. This
could lead to studies that look at the effectiveness of ALK inhibitors when used to treat
mood and cognitive disorders (1).
The EML4-ALK protein is dangerous because the tyrosine kinase domain from
the ALK gene can undergo ligand independent dimerization. This is possible because of
a coiled-coil domain from the EML4 gene. This interaction keeps the enzyme in a
constitutively active state, without the need for a ligand to regulate the process (6). As
long as ATP is present and able to bind, the EML4-ALK protein will keep pro-survival
signaling pathways active (8,6).
The general consensus is that the two main signaling pathways that are
activated by the active EML4-ALK fusion protein are the Ras/Raf/MEK/ERK pathway
and an abridged version of the JAK/STAT pathway (8,6). These two pathways are

illustrated in Figure 1. The activation of these pathways
results in the phosphorylation of the extracellular signalregulated kinase (ERK) and the signal transducer and activator
of transcription 3 (STAT3) proteins, respectively (6). The
Ras/Raf/MEK/ERK pathway is responsible for increasing the
rate of cell proliferation and decreasing apoptosis while the
2nd

Figure 1 shows two
messenger systems triggered by
the EML4-ALK oncoprotein.

phosphorylation of STAT3 decreases cell apoptosis by upregulating a pro-survival protein called survivin (4,6). Ardini

et. al. (1) claims that the STAT3 pathway is not a contributing factor in NSCLC, but
instead the PI3K-AKT pathway is more significant (1). The PI3K-AKT pathway leads to
the phosphorylation and activation of Protein Kinase B (PKB or AKT). This triggers
other signaling cascades, which can increase cell growth and proliferation, aid in
survival, and even help evade apoptosis (1).
Drug Facts
Crizotinib is a small molecule tyrosine kinase inhibitor sold by Pfizer under the
brand name Xalkori®. In some material it is referred to by its pre-market product name,
PF-2341066. It is approved for use to treat advanced stage or metastasized non-small cell
lung cancer that is ALK-positive (9). It is normally taken orally, twice daily in a 250 mg
tablet. If needed, the dose can be reduced to 200 mg twice daily and further reduced to
250 mg once daily. Crizotinib can be taken with or without food (4).

Chemically, crizotinib is 3-((R)-1-(2,6dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4yl)-1H-pyrazol-4-yl)pyridin-2-amine and is shown in
Figure 2. This gives it a molecular formula of
C21H22Cl2FN5O and a molecular weight of 450.34 Da
(3). Crizotinib is synthetically manufactured and was
originally designed as a c-MET (a different tyrosine
kinase) inhibitor. It was found that the tyrosine
kinase domains in both the c-MET and ALK proteins are similar enough that the specific
structure of crizotinib effectively binds with both (3). The conjugated ring structure
provides structural resonance and accurate positioning of binding sites (3). The
strategically placed 2-aminopyridine group and the ring nitrogen both form hydrogen
bonds to amino acid residues in the tyrosine kinase receptor, Glu 1197 and Met 1199
respectively. These bonds induce a conformational change that allows the other
substituents of the drug to block the binding of ATP. The chiral C-21 carbon has a
methyl group that must be in the R configuration in order for the drug to properly fit and
the methyl group’s hydrophobic properties also make the drug more attractive to the
lipophilic ATP binding pocket (8).
Crizotinib has moved with remarkable speed through the development and testing
phases. The specific abnormality that is the intended target (the ALK-positive mutation)
was not discovered until 2007 (9). It took until 2010 to validate ALK-positive proteins as
an effective drug target and by 2011 the FDA had approved the drug for clinical use (6).
At this time no generic alternative is available so patients are forced to spend as much as

$9600 a month on this new drug. Private insurance can reduce the cost considerably (to
as low as $30 a month) but because this is an oral medication and not intravenous like
typical chemotherapies, Medicare and Medicaid coverage is significantly lacking, but
that’s another paper.
Pharmacodynamics
As mentioned before, crizotinib enters the cell and binds to the lipophilic ATP
binding pocket. While bound, it acts as a competitive antagonist to ATP, forming
hydrogen bonds between the drug and amino acid residues in the tyrosine kinase receptor.
These bonds hold the drug in place while the rest of the molecule blocks the binding of
ATP through both placement and inducing a conformational change in the EML4-ALK
protein. Without ATP, the protein no longer has access to the phosphate groups that it
used to activate downstream cascades. This prevents the protein from ever reaching its
active state, essentially turning it off (8). The binding affinity of crizotinib is ten times
greater than that of ATP, so relatively low amounts of crizotinib are needed to produce
the desired effect (3).
The EML4-ALK protein is prevented from entering its active state because
crizotinib acts as a competitive antagonist to ATP. When crizotinib binds to the tyrosine
kinase domain, it induces a conformational change in the activation loop, preventing it
from accepting ATP, and thus, from becoming active (8). By preventing the activation of
the enzyme, crizotinib also indirectly inhibits the phosphorylation of ERK and STAT3
(and arguably, ATK). This leads to an increase in the rate of apoptosis in ALK-positive
cells (6).

Okamoto and Nakagawa found that the inhibited ERK pathway increased BIM
expression via induction by TAE684 (6). To put more simply, when crizotinib is present,
the ERK pathway becomes inhibited, indirectly. The inhibition of the ERK pathway
leads to an increase in concentration of the molecule TAE684. TAE684 then induces the
expression of pro-apoptotic BIM proteins. These proteins are pro-apoptotic because they
bind to and antagonize pro-survival members of its Bcl-2 family of proteins. The
antagonization of the pro-survival proteins negates their effects leads to apoptosis of the
cell (6).
STAT3 inhibition (via ALK inhibitors) also plays a role in the destruction of
ALK-positive cells. Survivin, a protein that prevents apoptosis by inhibiting caspase
proteins, is down-regulated to normal levels when the STAT3 pathway is no longer in a
constitutively active state. The decreased survivin levels lead to an increase in ALKinhibitor induced apoptosis (6).
As an alternative form of treatment, targeting each of these pathways
individually could, theoretically, work, but it would be, at best, impractical, if not
clinically impossible. Targeting each affected signaling pathway directly would likely be
less effective than ALK inhibition because of how much is unknown about the specific
pathways that are being utilized by the EML4-ALK protein. Even if all the pathways
were discovered and could be effectively inhibited, doing so would create much more and
more server side effects than a tyrosine kinase inhibitor because these pathways are used
for constructive means in healthy cells. They are necessary for survival in cells that are
disease-free unlike the ALK receptor (8).

Crizotinib binds to the ALK tyrosine kinases so easily that concentrations as low
as 20 nM produce half of the inhibitory effect (IC50) (3). This poses a potential issue for
side effects. Normally, when an enzyme is over-expressing itself, the goal is to reduce
the expression to normal levels. Crizotinib binds so well that it essentially turns the
EML4-ALK protein off. The reason this is not too much of a concern is because ALK
expression is not required for healthy living, as demonstrated by the ALK knockout mice
(1). Crizotinib also has the potential to bind to tyrosine kinase inhibitors other than those
in ALK. The molecular design process has tailored crizotinib to work best in ALK’s
binding pocket (3) and the therapeutic dose is low enough that most side effects are
completely manageable.
The most common reported side effects were gastrointestinal issues (nausea,
vomiting and diarrhea) and vision disorders (visual trailing and blurriness) (4). Most of
these side effects were either manageable or diminished over the course of treatment. In
less common, more server instances, there were reports of compromised immune
systems, pneumonitis, hepatotoxicity and more intense, prolonged GI disturbances (4).
On a clinical scale, crizotinib has shown to be effective at reducing tumor size in
ALK-positive patients. Over the course of two trials, encompassing 255 patients, there
were 3 complete responses and 136 partial responses. This translates to an objective
response rate of about 55% (9,4). Of those with an objective response, about 80% of
them occurred within the first 8 weeks of treatment (4). While these results look
promising, there is a significant downside. The median duration of the response was
limited to about 42 weeks (4). That means that, on average, the cancer will develop a
resistance to the drug in under a year. The most common mechanism for developing a

resistance is a secondary mutation within the tyrosine kinase domain of ALK that
minimizes crizotinib’s binding affinity. Normally, the secondary mutation would involve
substituting a larger amino acid into the area that forms the ATP binding pocket. The
larger amino acid, if placed correctly, could prevent crizotinib from binding but still
allow ATP to bind (9). This mutation could potentially open up new vulnerabilities in the
cancer that could be exploited by another drug.
Pharmacokinetics
Crizotinib is normally administered orally, twice daily in 250 mg pills. Peak
plasma concentrations (Cmax) after a single dose were typically reached within 6 hours at
a level of 131 ng/mL (4). With a half-life (t1/2) of 42 hours, it takes 15 days of
administration to reach the steady state plasma concentration (4). The median minimum
(trough) plasma concentration was 256 ng/mL, which is high enough to provide full
efficacy (4). It was noted that both peak plasma concentration and area under the curve
were about 1.5 times greater in Asian patients compared to their non-Asian counterparts
(4). No explanation has been offered for this observation.
The volume of distribution averaged out to be 1772 L with 91% of the blood
borne drug bound to plasma proteins (4). Elimination from healthy volunteers was
primarily through the feces (63%) with 53% being unchanged. The urine accounted for
the elimination of 22% of the drug (2.3% unchanged) (4). Primary metabolization was
done by cytochrome P450 (CYP) 3A4/5. It was done by first, oxidizing the piperidine
ring, followed by dealkylation. The dealkylated products were then conjugated (made
water soluble) before being excreted (4).

Other
It was noted that, because crizotinib was metabolized by CYP 3A4/5,
coadministration with either CYP3A inducers or inhibiters altered both the AUC and
Cmax. When taken in conjunction with strong CYP3A inducers, crizotinib’s AUC and
Cmax dropped by 82 and 69% respectively (4). When taken with strong CYP3A
inhibitors, those levels jumped 3.2 and 1.4 times, respectively (4). These findings make
sense because with more CYP3A that is available to metabolize crizotinib (in the case
with the inducer), the faster crizotinib could be broken down. In the case of the inhibitor,
the drug can remain in the system longer because the enzyme responsible for its
metabolization is otherwise occupied. Crizotinib itself is a moderate CYP3A inhibitor so
care must be taken when crizotinib is administered in conjunction with something that is
metabolized by CYP3A (4).
Crizotinib was chosen for the topic of this paper because the author’s mother is
currently being treated with it. She was diagnosed with stage 3 adenocarcinoma in the
spring of 2006. After surgery, chemo and radiation she had no evidence of disease until
the fall of 2010. One of her routine scans turned up a spot on her lung and a subsequent
MRI turned up two small lesions in her brain. Fortunately, a combination of whole brain
radiation and erlotinib (Tarceva®) shrunk both abnormalities significantly. That course of
treatment seemed to be holding the disease at bay for a time but a recent scraping from a
bronchoscopy turned up live cancer cells and the following bone scan showed a large
mass in her sacrum. Palliative radiation has reduced her sacral pain considerably and
results regarding tumor shrinkage or bone regeneration are still pending. She started
taking Xalkori® (crizotinib) in January of 2013 and she is experiencing minimal side

effects. She has reported small amounts of manageable nausea and some of the visual
disorders described above. She does not find the visual disturbances too distracting and
has claimed to enjoy and embrace the alternate perception of reality that they offer.
In clinical trials, crizotinib has seen great initial success. Through two studies, its
objective response rate averaged about 55% with minimal side effects. Unfortunately,
resistance developed in 100% of cases with an objective response in an average of 42
weeks. This was done mainly through secondary mutations in the tyrosine kinase domain
of the ALK portion of the EML4-ALK gene. This drug has shown that medicine
designed for a very specific disease has the potential to be effective.
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